flow trial semaglutide renal outcomes 2024 🚨 Journal Club: Review 🚨 The FLOW Trial, published in flow trial semaglutide kidney outcomes

It blocks the Sodium-Glucose Co-Transporter 2 (SGLT2) protein in the renal tubules

Lower levels of IGF-1 and growth hormone in older adults have been linked with (5, 14): increased fat mass increased cardiovascular risk decreased muscle mass and strength lower cognitive function lower bone density limited joint mobility Several of these traits are seen in frail older adults

My role focused on graphic and packaging design, ensuring a cohesive and impactful visual identity for the product line

Neuropharmacology 62 , 19161927 (2012)

Using the lowest dose that works reduces both side effects and treatment costs while maintaining benefits